APC Promoter Hypermethylation and Survival in Esophageal Cancer
Author Information
Author(s): Zare Maryam, Rastgar Ferdous, Alivand Mohammad Reza, Nasseri Negin Karimi, Malekzadeh Reza, Yazdanbod Mansour
Primary Institution: National Institute of Genetic Engineering & Biotechnology (NIGEB), Tehran, Iran
Hypothesis
Is APC promoter hypermethylation associated with survival in patients with esophageal cancer?
Conclusion
APC promoter hypermethylation is linked to lower survival rates in patients with esophageal cancer.
Supporting Evidence
- 44.4% of tumor tissues showed APC promoter hypermethylation.
- Patients with unmethylated APC promoter had a higher two-year survival rate.
- Statistical tests indicated a significant association between APC methylation and mortality.
Takeaway
This study found that patients with a specific gene change (APC promoter hypermethylation) had a harder time surviving after treatment for esophageal cancer.
Methodology
Qualitative methylation specific PCR was used to evaluate APC promoter hypermethylation and its association with survival in SCCE patients.
Limitations
The study may require additional samples for moderate and well differentiated tumors to draw more definitive conclusions.
Participant Demographics
45 patients (27 men and 18 women) aged 23 to 80, with various tumor differentiation statuses.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website